There’s too many here who think this is sunk, when in fact, it’s still very much unrealized. All the folks who cry out for Denner to talk need to realize his moves are light years ahead.
I have no doubt the golden goose will be realized. I’m still adding to my position and still bullish on what’s to come.
Mr. S Great post, accurate and positive, had to be to illicit a response from LBL who has always ben a voice of reason and knowledge. Know what you own. Denner sure does.
Stockboy, I love the enthusiasm. And I don't totally disagree.
YES, generics cannot directly copy a Vascepa combo drug. However, nothing is preventing doctors/pharmacists/insurers from simply saying "just take gIPE plus this statin/diabetes drug/etc. - it's MUCH cheaper and just an extra pill!"
Point is, Denner et.al. has to convince a BP that they can retain exclusivity *in practice* (vs. "legal" exclusivity).
Amarin has multiple next generation Vascepa-Plus in the works
Since when? They've only talked about a V + statin combo drug in the past - I haven't seen this new patent yet, but it could be just a way to prevent generics from making a different combo drug - not that AMRN has any intention of spending the money needed to actually run a trial and try to get it FDA approved. Hell, they've had the statin combo patent for many years and haven't done a damn thing with it, beyond maybe some pre-clinical petri dish studies.
Does Not matter if the patent can't be copied, what matters is what insurers dictate to be prescribed. If AMRN can convince FDA they are only drug in class then according Affordable Helath Care Act the med has to be covered. However, my guess is insurers will argue EPA is EPA refined or not and its all being used for VHTG.
News 
Market Data 
Discover 
AI
